跳至主要内容
临床试验/JPRN-UMIN000010332
JPRN-UMIN000010332招募中4 期

A Randomized Parallel Group Controlled Study between 3.75 mg of Leuprorelin and 1.8 mg of Goserelin Depot in the Sequential Therapy (GnRH Agonist + Dienogest) for Treatment of Endometriosis - A Randomized Parallel Group Controlled Study between 3.75 mg of Leuprorelin and 1.8 mg of Goserelin Depot in the Sequential Therapy (GnRH Agonist + Dienogest) for Treatment of Endometriosis

Tokyo Women's Medical University Department of Obstetrics and Gynecology0 个研究点目标入组 120 人开始时间: 2013年3月28日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1. Patients with undiagnosed abnormal genital bleeding 2. Pregnant or possibly pregnant women 3. Lactating patients 4. Patients with a past history of hypersensitivity to GnRH agonists or dienogest 5. Patients treated with hormone drugs (oral contraceptive, danazol, GnRH agonists, etc.) and dienogest within the past 4 months 6. Other patients considered ineligible as subjects by investigator

研究者

发起方
Tokyo Women's Medical University Department of Obstetrics and Gynecology

相似试验